Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban in Pediatric Heart Disease (SAXOPHONE)
NCT02981472Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2017
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial of apixaban in thromboembolism (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Composite of Adjudicated Major or Clinically Relevant Non-Major (CRNM) Bleeding Events at 12 months. Started Jan 2017; status: completed.
02
Drugs
apixaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02981472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02981472.